

General Partner of which is Erwin Russel, and the Amazonite Family Limited Partnership, is revised to read as follows:

1. *Trevor R. Burgess, St. Petersburg, Florida; Marcio Camargo, Marcelo Lima, Erwin Russel, all of São Paulo, Brazil; CBM Holdings Qualified Family, L.P. Toronto, Ontario, Canada, with Marcelo Lima as general partner, and C1 Financial Holdings Qualified Family, L.P., Toronto, Ontario, Canada, with Erwin Russel as general partner; to acquire voting shares of C1 Financial, Inc., and thereby indirectly acquire voting shares of C1 Bank, both in St. Petersburg, Florida.*

Comments on this application must be received by August 25, 2014.

Board of Governors of the Federal Reserve System, August 14, 2014.

**Michael J. Lewandowski,**

*Associate Secretary of the Board.*

[FR Doc. 2014-19619 Filed 8-18-14; 8:45 am]

**BILLING CODE 6210-01-P**

## FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of

Governors not later than September 12, 2014.

A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. *First Midwest Bancorp, Inc.*, Itasca, Illinois; to merge with Great Lakes Financial Resources, Bancorp, Inc., Matteson, Illinois, and thereby indirectly acquire Great Lakes Bank, N.A., Blue Island, Illinois.

B. Federal Reserve Bank of Dallas (E. Ann Worthy, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Catahoula Holding Company*, Jonesville, Louisiana; to acquire 100 percent of the voting shares of JBI Financial Corporation, and thereby indirectly acquire voting shares of Bank of Jena, both in Jena, Louisiana.

Board of Governors of the Federal Reserve System, August 14, 2014.

**Michael J. Lewandowski,**

*Associate Secretary of the Board.*

[FR Doc. 2014-19620 Filed 8-18-14; 8:45 am]

**BILLING CODE 6210-01-P**

## GENERAL SERVICES ADMINISTRATION

[OMB Control No. 3090-00XX; Docket No. 2014-0001; Sequence No. 7]

### Submission for OMB Review; MyUSA

**AGENCY:** Office of Citizen Services and Innovative Technologies (OCSIT), General Services Administration (GSA).

**ACTION:** Notice of request for comments regarding a request for a new information collection.

**SUMMARY:** Under the provisions of the Paperwork Reduction Act (44 U.S.C. chapter 35), the Regulatory Secretariat Division will be submitting to the Office of Management and Budget (OMB) a request for a new information collection concerning MyUSA.

**DATES:** Submit comments on or before September 18, 2014.

**ADDRESSES:** Submit comments identified by Information Collection 3090-00XX; MyUSA by any of the following methods:

- *Regulations.gov:* <http://www.regulations.gov>. Submit comments via the Federal eRulemaking portal by searching the OMB control number 3090-00XX. Select the link "Comment Now" that corresponds with "Information Collection 3090-00XX; MyUSA". Follow the instructions provided at the "Submit a Comment" screen. Please include your name, company name (if any), and

"Information Collection 3090-00XX; MyUSA" on your attached document.

- *Mail:* General Services Administration, Regulatory Secretariat Division (MVCB), 1800 F Street NW., 2nd Floor, Washington, DC 20405-0001. ATTN: IC 3090-00XX; MyUSA.

*Instructions:* Please submit comments only and cite Information Collection 3090-00XX; MyUSA, in all correspondence related to this collection. All comments received will be posted without change to <http://www.regulations.gov>, including any personal and/or business confidential information provided.

### FOR FURTHER INFORMATION CONTACT:

Joseph Polastre, Innovation Specialist, 1800 F Street NW., Washington, DC 20405-0001, telephone 202-317-0077. For information pertaining to status or publication schedules, contact the Regulatory Secretariat Division at 202-501-4755.

### SUPPLEMENTARY INFORMATION:

#### A. Purpose

MyUSA (<https://my.usa.gov>) provides an account to users that gives them control over their interactions with government agencies and how government uses and accesses their personal information. Users have the option of creating a personal profile that can be reused across government to personalize interactions and streamline common tasks such as filling out forms. Government agencies can build applications that can request permission from the user to access their MyUSA Account and read their personal profile.

The information in the system is contributed voluntarily by the user and cannot be accessed by the government without explicit consent of the user; information is not shared between government agencies, except when the user gives explicit consent to share his or her information, and as detailed in the MyUSA System of Records Notice (SORN) (<http://www.gpo.gov/fdsys/pkg/FR-2013-07-05/pdf/2013-16124.pdf>).

The information collected is basic profile information, and may include: name, email address, home address, phone number, date of birth, gender, marital status and basic demographic information such as whether the individual is married, a veteran, a small business owner, a parent or a student.

Use of the system, and contribution of personal information, is completely voluntary. A notice was published November 29, 2013. No comments were received.

#### B. Public Comments

Public comments are particularly invited on: Whether this collection of

information is necessary for the proper performance of functions of the Reporting and Use of Information Concerning Integrity and Performance of Recipients of Grants and Cooperative Agreements, whether it will have practical utility; whether our estimate of the public burden of this collection of information is accurate, and based on valid assumptions and methodology; ways to enhance the quality, utility, and clarity of the information to be collected; and ways in which we can minimize the burden of the collection of information on those who are to respond, through the use of appropriate technological collection techniques or other forms of information technology.

### C. Annual Reporting Burden

*Respondents:* 10,000.

*Responses per Respondent:* 1.

*Total annual responses:* 10,000.

*Hours per Response:* .05.

*Total Burden Hours:* 500.

*Obtaining Copies of Proposals:*

Requesters may obtain a copy of the information collection documents from the General Services Administration, Regulatory Secretariat Division (MVCB), 1800 F Street NW., 2nd Floor, Washington, DC 20405-0001, telephone 202-501-4755. Please cite OMB Control No. 3090-00XX, MyUSA, in all correspondence.

Dated: August 13, 2014.

**Sonny Hashmi,**

*Chief Information Officer, Office of the Chief Information Officer.*

[FR Doc. 2014-19604 Filed 8-18-14; 8:45 am]

**BILLING CODE 6820-34-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2014-N-0012]

### Clinical Studies of Safety and Effectiveness of Orphan Products Research Project Grant (R01)

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of grant funds for the support of FDA's Office of Orphan Products Development grant program. The goal of FDA's Orphan Products Development (OPD) grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product

will be superior to the existing therapy. FDA provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products. Applicants must include in the application's Background and Significance section documentation to support the assertion that the product to be studied meets the statutory criteria to qualify for the grant and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.

**DATES:** Important dates are as follows:

1. The application due dates are February 4, 2015; February 3, 2016; February 1, 2017; and February 7, 2018.

The resubmission due dates are October 15, 2015; October 14, 2016; October 16, 2017; and October 15, 2018.

2. The anticipated start dates are November 2015; November 2016; November 2017; and November 2018.

3. The opening date is December 4, 2014.

4. The expiration dates are February 8, 2018, and October 16, 2018, (resubmission).

**ADDRESSES:** Submit electronic applications to: <http://www.grants.gov>. For more information, see section III of the **SUPPLEMENTARY INFORMATION** section of this notice.

### FOR FURTHER INFORMATION AND

### ADDITIONAL REQUIREMENTS CONTACT:

Katherine Needleman, Director, Orphan Products Grants Program, Office of Orphan Products Development, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5295, Silver Spring, MD 20993-0002, 301-796-8660, [katherine.needleman@fda.hhs.gov](mailto:katherine.needleman@fda.hhs.gov); or Vieda Hubbard, Grants Management Specialist, Division of Acquisition Support and Grants, Office of Acquisitions & Grant Services, 5630 Fishers Lane, Rockville, MD 20857, 240-402-7588, [vieda.hubbard@fda.hhs.gov](mailto:vieda.hubbard@fda.hhs.gov).

For more information on this funding opportunity announcement (FOA) and to obtain detailed requirements, please refer to the full FOA located at <http://grants.nih.gov/grants/guide> (select the "Request for Applications" link), <http://www.grants.gov> (see "For Applicants" section), and <http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/WhomtoContactaboutOrphanProductDevelopment/ucm134580.htm>.

### SUPPLEMENTARY INFORMATION:

### I. Funding Opportunity Description

RFA-FD-15-001  
93.103

### A. Background

The OPD was created to identify and promote the development of orphan products. Orphan products are drugs, biologics, medical devices, and medical foods that are indicated for a rare disease or condition. The term "rare disease or condition" is defined in section 528 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ee). FDA generally considers drugs, devices, and medical foods potentially eligible for grants under the OPD grant program if they are indicated for a disease or condition that has a prevalence, not incidence, of fewer than 200,000 people in the United States. Diagnostics and vaccines are considered potentially eligible for such grants only if the U.S. population to whom they will be administered is fewer than 200,000 people in the United States per year.

### B. Research Objectives

The goal of FDA's OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy. FDA provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products. Applicants must include in the application's Background and Significance section documentation to support the assertion that the product to be studied meets the statutory criteria to qualify for the grant and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.

### C. Eligibility Information

The grants are available to any foreign or domestic, public or private, for-profit or nonprofit entity (including State and local units of government). Federal Agencies that are not part of the Department of Health and Human Services (HHS) may apply. Agencies that are part of HHS may not apply. For-profit entities must commit to excluding fees or profit in their request for support to receive grant awards. Organizations that engage in lobbying activities, as described in section 501(c)(4) of the Internal Revenue Code of 1968, are not eligible to receive grant awards.

## II. Award Information/Funds Available

### A. Award Amount

Of the estimated Fiscal Year (FY) 2016 funding (\$14.1 million), approximately \$10 million will fund noncompeting continuation awards, and